中草药

中药调控免疫微环境干预肺癌的研究进展

PDF下载

洪梅, 唐若天, 赵乃义, 周相儒, 谭敏, 陆冬, 匡大鹏, 郑广勇

中草药 | 综述 2026,57(9): 3622-3635

收起

中草药 |综述 2026 , 57 (9) : 3622 -3635

中药调控免疫微环境干预肺癌的研究进展

全屏

洪梅, 唐若天, 赵乃义, 周相儒, 谭敏, 陆冬, 匡大鹏, 郑广勇

作者信息

通讯作者:

匡大鹏

作者简介:

洪梅: 洪梅,硕士研究生,研究方向为中药复方干预肺癌的分子机制。E-mail:hongmei010106@163.com

Research progress on traditional Chinese medicine-regulated immune microenvironment for lung cancer intervention

HONG Mei, TANG Ruotian, ZHAO Naiyi, ZHOU Xiangru, TAN Min, LU Dong, KUANG Dapeng, ZHENG Guangyong

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.09.030

文章导航

摘要

收起

肺癌是一种全球范围内发病率和死亡率均较高的恶性肿瘤。近年来，中药方剂在调控肿瘤免疫微环境（tumor immune microenvironment，TME）及辅助肺癌治疗方面取得了突破性进展。然而，由于中药方剂具有多成分、多靶点、多途径协同作用的特点，解析其调控TME的作用机制仍面临巨大挑战。通过系统总结中医对肺癌病因病机的认识及临床治疗原则，深入探讨了中药调控TME的分子机制，并对未来解读复方调控TME作用机制的研究策略进行展望，为推动复方在肺癌临床治疗中的精准用药提供依据。

关键词

肺癌 / 中药方剂 / 免疫调控 / 精准用药 / 肿瘤免疫微环境

Abstract

收起

Lung cancer is a malignant tumor with high incidence and mortality rates in the global. In recent years, traditional Chinese medicine (TCM) formulas have achieved breakthrough progress in regulating the tumor immune microenvironment (TME) and serving as adjuvant therapy for lung cancer. However, due to the multi-component, multi-target, and multi-pathway synergistic effects of TCM formulas, elucidating their mechanisms of regulating TME remains a significant challenge. This review systematically summarizes TCM’s understanding of the etiology and pathogenesis of lung cancer, as well as clinical treatment principles. It further explores the molecular mechanisms by which TCM regulates tumor immune microenvironments and provide insights into future research strategies for deciphering the mechanisms underlying the regulation of TME by TCM formulas. This review aims to provide a theoretical basis for understanding TCM-mediated TME regulation against lung cancer and promoting the precise application of TCM formulas in clinical lung cancer treatment.

Key words

lung cancer / Chinese medicine formula / immune regulation / precision medicine / tumor immune microenvironment

引用本文

洪梅, 唐若天, 赵乃义, 周相儒, 谭敏, 陆冬, 匡大鹏, 郑广勇. 中药调控免疫微环境干预肺癌的研究进展. 中草药, 2026 , 57 (9) : 3622 -3635 . DOI: 10.7501/j.issn.0253-2670.2026.09.030

HONG Mei, TANG Ruotian, ZHAO Naiyi, ZHOU Xiangru, TAN Min, LU Dong, KUANG Dapeng, ZHENG Guangyong. Research progress on traditional Chinese medicine-regulated immune microenvironment for lung cancer intervention[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (9) : 3622 -3635 . DOI: 10.7501/j.issn.0253-2670.2026.09.030

基金

收起

国家自然科学基金资助项目(82360767);国家自然科学基金资助项目(U23A20521);广西中医药大学基金资助项目(2023BS058,2024ZD004);中药壮瑶药创新药物教育部工程研究中心项目(ZYZYY2025016);广西疑难重症中医诊疗研究团队(2022A001);广西岐黄学者培养项目(GXQH202404)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Wang M N, Herbst R S, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer[J].Nat Med, 2021, 27(8):1345-1356.
Miller M, Hanna N. Advances in systemic therapy for nonsmall cell lung cancer[J]. Bmj, 2021:n2363.
肖祥,吴宣諭,韩洁榕,等.“肺与大肠相表里”视角下探索肠道菌群与肺癌因果关联及潜在干预中药预测[J].中草药, 2024, 55(12):4108-4120.
World Health Organization. Lung cancer[EB/OL].(2023-04-11)[2025-09-14]. https://www.who.int/news-room/fact-sheets/detail/lung-cancer.
Chen Z, Fillmore C M, Hammerman P S, et al. Non-smallcell lung cancers:A heterogeneous set of diseases[J]. Nat Rev Cancer, 2014, 14(8):535-546.
Chen D S, Mellman I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637):321-330.
Wang J Y, Liu T, Huang T, et al. The mechanisms on evasion of anti-tumor immune responses in gastric cancer[J]. Front Oncol, 2022, 12:943806.
Liu X W, Song J N, Zhang H, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance[J]. Cancer Cell,2023, 41(2):272-287.
Huang C X, Lao X M, Wang X Y, et al. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma[J]. Cancer Cell, 2024, 42(12):2082-2097.
Zhang Y, Guo Y B, Liu Z Q, et al. Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance[J]. Cell, 2025, 188(24):6754-6773.
Wang Z Y, Du X P, Xing X X, et al. Myeloid-derived suppressor cells:Orchestrators of tumor immune evasion and therapeutic vulnerabilities[J]. Mol Cancer Res, 2025,23(10):829-838.
Jin R, Neufeld L, McGaha T L. Linking macrophage metabolism to function in the tumor microenvironment[J].Nat Cancer, 2025, 6(2):239-252.
You S Y, Li S Q, Zeng L S, et al. Lymphatic-localized TregmregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity[J]. Cancer Cell, 2024, 42(8):1415-1433.
Li Z Y, Pai R, Gupta S, et al. Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy[J]. Nat Cancer, 2024, 5(1):167-186.
Zheng H L, Wang G, Liu M, et al. Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy:A literature review[J]. Front Oncol,2023, 13:1168226.
Yang L, Han X Y, Wang M X, et al. Early growth response gene 1 benefits autoimmune disease by promoting regulatory T cell differentiation as a regulator of FoxP3[J].Research, 2025, 8:662.
田建辉,罗斌,刘嘉湘.肺癌“正虚伏毒”病机的生物学基础(一):基于免疫紊乱之肺癌“正虚”探要[J].上海中医药杂志, 2018, 52(1):1-4.
田建辉,罗斌.肺癌“正虚伏毒”病机的生物学基础(二):基于隐匿性肿瘤细胞之肺癌“伏毒”病机探要[J].上海中医药杂志, 2018, 52(2):6-10.
方美花,姚文亿,许征国.沙参麦冬汤加减联合常规西医疗法治疗气阴两虚型肺癌42例[J].河南中医, 2020,40(12):1875-1878.
刘石.参芪固金汤通过抑制FGFR2/ERK1/2通路对非小细胞肺癌凋亡、增殖和迁移的影响[D].长沙:湖南中医药大学, 2024.
尹艳芬.中晚期非小细胞肺癌化疗后白细胞减少症中医证型分布及相关因素研究[D].济南:山东中医药大学, 2024.
何加力.扶正抑癌方对正虚癌毒型非小细胞肺癌(非鳞癌)的临床研究[D].扬州:扬州大学, 2024.
顾军花,刘嘉湘.刘嘉湘教授“扶正治癌”理论核心及运用方法[J].中国中西医结合杂志, 2017, 37(4):495-499.
杨丙雨,李桂君,陈昱昊,等.清金化痰汤联合化疗对痰热壅肺证肺癌中医症状积分及血清CYFRA21-1、TGF-β1的影响[J].中华保健医学杂志, 2025, 27(2):249-252.
何佳琪,张雨田,冯彬彬,等.基于“中焦壅塞,阴火毒炽”探析肝癌“炎-癌转化”的病机特点与防治策略[J].中国中西医结合外科杂志, 2025, 31(6):944-948.
孙晓林,王海滨.基于网络药理学与分子对接探讨调卫抑癌方治疗非小细胞肺癌作用机制[J].亚太传统医药, 2026, 22(2):28-35.
Vinod S K, Hau E. Radiotherapy treatment for lung cancer:Current status and future directions[J]. Respirology, 2020,25(Suppl 2):61-71.
赵梓行,张兰鑫,胡帅航,等.从“因加而发”探讨非小细胞肺癌术后复发转移的病机及防治[J].北京中医药大学学报, 2025, 48(12):1743-1749.
张博,王伟昱,李斌,等.扶正祛邪方通过PI3K/Akt/m TOR信号通路下调SREBP表达抑制肺癌增殖与侵袭转移的实验研究[J/OL].辽宁中医杂志,(2025-10-27)[2026-01-09]. https://link.cnki.net/urlid/21.1128.R.20251024.1731.104.
林丽珠,王思愚,黄学武.肺癌中西医结合诊疗专家共识[J].中医肿瘤学杂志, 2021, 3(6):1-17.
刘文瑞,冯贞贞,雷斯媛,等.基于临床调查的非小细胞肺癌常见症状群及其对证候贡献度的确定[J].世界中医药, 2025, 20(15):2731-2738.
何裕民.现代中医肿瘤学[M].北京:中国协和医科大学出版社, 2005.
安佳丽.中成药治疗非小细胞肺癌的临床证据评价[D].天津:天津中医药大学, 2024.
冯一帆,宋亚刚,苗晋鑫,等.基于数据挖掘的中医药干预肿瘤复发的宏观规律分析[J].时珍国医国药,2026, 37(3):587-592.
肖巧,侯炜.从活血化瘀法论治贝伐珠单抗所致高血压[J].中国民间疗法, 2025, 33(20):31-33.
李倩,王海龙,李琪,等.六君子汤联合艾灸治疗脾虚痰湿型肺癌患者癌因性疲乏的效果[J].吉林医学,2025, 46(10):2483-2486.
林丹丹.沙参麦冬汤加减对肺癌化疗患者气阴两虚证的改善效果及对免疫功能、生活质量的影响[J].中国中医药科技, 2025, 32(6):1004-1006.
宋东升,庞志勇.益气化痰方联合吉非替尼片治疗气虚痰浊型中晚期非小细胞肺癌的研究[J].中医研究,2024, 37(7):28-33.
王忠旭.补金益髓汤防治非小细胞肺癌化疗后骨髓抑制的临床研究[D].武汉:湖北中医药大学, 2023.
石海波.消癌解毒方联合化疗治疗晚期非小细胞肺癌(痰瘀郁毒型)的临床观察[D].南京:南京中医药大学, 2018.
肖朝霞.健脾祛痰方联合GP方案治疗中晚期非小细胞肺癌的临床观察[D].长沙:湖南中医药大学, 2016.
陈倩倩,王海龙,郭政钰,等.消岩汤姑息治疗中晚期非小细胞肺癌的回顾性临床研究[J].中草药, 2024,55(5):1620-1626.
朱海生,严浩林,黄文丽.复方苦参注射液联合放疗治疗老年晚期非小细胞肺癌疗效观察[J].山西中医,2011, 27(6):23-25.
王学语.参芪益肺汤治疗气阴两虚型晚期非小细胞肺癌的临床观察[D].济南:山东中医药大学, 2021.
程晓玉,贾英杰,李小江,等.扶正解毒祛瘀方联合化疗治疗非小细胞肺癌30例临床观察[J].湖南中医杂志, 2015, 31(9):3-5.
Sun K X, Wu L, Wang S Y, et al. Antitumor effects of Chinese herbal medicine compounds and their nanoformulations on regulating the immune system microenvironment[J]. Front Oncol, 2022, 12:949332.
Xu Q, Cheng W, Wei J R, et al. Synergist for antitumor therapy:Astragalus polysaccharides acting on immune microenvironment[J]. Discov Oncol, 2023, 14(1):179.
Yao P Y, Liang S, Liu Z Y, et al. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer[J]. Front Immunol, 2024, 15:1343316.
Bensenane R, Helfre S, Cao K, et al. Optimizing lung cancer radiation therapy:A systematic review of multifactorial risk assessment for radiation-induced lung toxicity[J]. Cancer Treat Rev, 2024, 124:102684.
Xu F, Cui W Q, Wei Y, et al. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling[J]. J Exp Clin Cancer Res, 2018, 37(1):207.
Qin Z T, Wu Z H, Wang C M, et al. Astragalus polysaccharide as a potential antitumor immunomodulatory drug(Review)[J]. Mol Med Rep,2025, 32(6):1-16.
Wang W, Kong M, Shen F, et al. Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer[J]. Front Immunol, 2024, 15:1434078.
Hirsch F R, Scagliotti G V, Mulshine J L, et al. Lung cancer:Current therapies and new targeted treatments[J].Lancet, 2017, 389(10066):299-311.
Zhao B, Hui X D, Wang J, et al. Matrine suppresses lung cancer metastasis via targeting M2-like tumourassociated-macrophages polarization[J]. Am J Cancer Res, 2021, 11(9):4308-4328.
Wu C Y, Yang Y H, Lin Y S, et al. The effect and mechanism of Astragalus polysaccharides on T cells and macrophages in inhibiting prostate cancer[J]. Biomed J,2025, 48(1):100741.
Wei Z C, Chen J, Zuo F, et al. Traditional Chinese medicine has great potential as candidate drugs for lung cancer:A review[J]. J Ethnopharmacol, 2023, 300:115748.
Qian J N, Jiang Y Y, Hu H Y. Ginsenosides:An immunomodulator for the treatment of colorectal cancer[J]. Front Pharmacol, 2024, 15:1408993.
Su X L, Wang J W, Che H, et al. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer[J]. Chin Med J, 2020, 133(24):2987-2997.
Guldenpfennig C, Teixeiro E, Daniels M. NF-kB’s contribution to B cell fate decisions[J]. Front Immunol,2023, 14:1214095.
Zhang L L, Xiao H, Zhang F, et al. BAFF, involved in B cell activation through the NF-κB pathway, is related to disease activity and bone destruction in rheumatoid arthritis[J]. Acta Pharmacol Sin, 2021, 42(10):1665-1675.
Jiang Y, Liu L S, Shen L P, et al. Traditional Chinese medicine treatment as maintenance therapy in advanced non-small-cell lung cancer:A randomized controlled trial[J]. Complement Ther Med, 2016, 24:55-62.
代雨鑫,梁立春,彭琳茜,等.齐墩果酸对B淋巴细胞损伤的保护作用并基于网络药理学探索其作用机制[J].癌变·畸变·突变, 2024, 36(1):48-52.
Wang S F, Wang Q, Jiao L J, et al. Astragalus-containing traditional Chinese medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer:A systemic review and Meta-analysis[J]. Curr Oncol, 2016, 23(3):188-195.
程帅,刘松江.山慈菇在中晚期肺癌的药理作用及作用机制研究进展[J].临床医学进展, 2025, 15(6):491-497.
Hong G, Chen X, Sun X, et al. Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations[J]. Precis Clin Med, 2019, 2(4):235-245.
Guo L, Bai S P, Zhao L, et al. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer:Effects on quality of life and survival[J]. Med Oncol, 2012, 29(3):1656-1662.
宋炳生,杨玉龙.枸杞多糖的免疫调节作用[J].药学实践与服务, 1997, 15(2):69-72.
刘思,宋娟,洋雯茜,等.枸杞多糖结构特征、生物活性及其降解研究进展[J].中草药, 2025, 56(4):1440-1455.
程曦,黄凝,李鸿泉,等.枸杞多糖通过调节免疫在肿瘤免疫治疗中的应用前景分析[J].中医药学报, 2022,50(2):1-4.
Seweryn E, Ziała A, Gamian A. Health-promoting of polysaccharides extracted from Ganoderma lucidum[J].Nutrients, 2021, 13(8):2725.
Wang M, Yu F. Research progress on the anticancer activities and mechanisms of polysaccharides from Ganoderma[J]. Front Pharmacol, 2022, 13:891171.
Wu Z W, Zhao X F, Quan C X, et al. Structure-function insights of natural Ganoderma polysaccharides:Advances in biosynthesis and functional food applications[J]. Nat Prod Bioprospect, 2025, 15(1):15.
Xavier Raj I, Kyun Koh W, Harrison J, et al. Noncanonical functions of DNMT3A in hematopoietic stem cells regulate telomerase activity and genome integrity[J].Cell Stem Cell, 2025, 32(8):1251-1266.e8.
Li M Y, Yang Y H, Xiong L T, et al. Metabolism,metabolites, and macrophages in cancer[J]. J Hematol Oncol, 2023, 16(1):80.
Li A Q, Huang F, Talaiti S, et al. Understanding the complexity of tumor-associated macrophages:Druggable and therapeutic insights[J]. Acta Pharm Sin B, 2025,15(9):4456-4475.
Peng M Y, Li N N, Wang H B, et al. Macrophages:Subtypes, distribution, polarization, immunomodulatory functions, and therapeutics[J]. MedComm, 2025, 6(8):e70304.
Shen M Y, Li Z, Wang J, et al. Traditional Chinese herbal medicine:Harnessing dendritic cells for anti-tumor benefits[J]. Front Immunol, 2024, 15:1408474.
You Y P, Yan L, Ke H Y, et al. Baicalin inhibits PANoptosis by blocking mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly in macrophages[J]. Acta Pharmacol Sin, 2025, 46(2):430-447.
Li M X, Wu J Z, Li D, et al. Baicalin ameliorates dextran sulfate solidum-induced colitis by modulating Th17-macrophage immune network via JAK2/STAT3/IL-17/NF-κB pathway[J]. Phytomedicine, 2025, 148:157414.
Chen J R, Liu J, Cao X T. Functional and metabolic heterogeneity of dendritic cells in self-tolerance and autoimmunity[J]. Immunol Rev, 2025, 336(1):e70068.
Pittet M J, Di Pilato M, Garris C, et al. Dendritic cells as shepherds of T cell immunity in cancer[J]. Immunity,2023, 56(10):2218-2230.
Fucikova J, Palova-Jelinkova L, Bartunkova J, et al.Induction of tolerance and immunity by dendritic cells:Mechanisms and clinical applications[J]. Front Immunol,2019, 10:2393.
Morante-Palacios O, Fondelli F, Ballestar E, et al.Tolerogenic dendritic cells in autoimmunity and inflammatory diseases[J]. Trends Immunol, 2021, 42(1):59-75.
Liu Z M, Zhu H B, Zhang F X, et al. Dendritic cell-derived MyD88 potentiates as a biomarker for immune regulation in hepatocellular carcinoma and may predict a better immunological result[J]. Front Cell Dev Biol, 2025, 13:1554705.
Parvanian S, Ge X Y, Garris C S. Recent developments in myeloid immune modulation in cancer therapy[J]. Trends Cancer, 2025, 11(4):365-375.
Hegde S, Giotti B, Soong B Y, et al. Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours[J]. Nature, 2025, 646(8087):1214-1222.
Miller T E, El Farran C A, Couturier C P, et al. Programs,origins and immunomodulatory functions of myeloid cells in glioma[J]. Nature, 2025, 640(8060):1072-1082.
Zhai Y J, Liang X T, Deng M. Myeloid cells meet CD8+T cell exhaustion in cancer:What, why and how[J]. Chin J Cancer Res, 2024, 36(6):616-651.
Juric V, Mayes E, Binnewies M, et al. TREM1 activation of myeloid cells promotes antitumor immunity[J]. Sci Transl Med, 2023, 15(711):eadd9990.
Li Y H, Li H, He Q J, et al. Potential of compounds originating from the nature to act in hepatocellular carcinoma therapy by targeting the tumor immunosuppressive microenvironment:A review[J].Molecules, 2023, 28(1):195.
Karin E. de Visser, Johanna A. Joyce. The evolving tumor microenvironment:From cancer initiation to metastatic outgrowth[J]. Cancer Cell. 2023, 41(3):374-403.
Zhang J T, Liu S, Chen X B, et al. Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy[J]. Biomed Pharmacother, 2023,166:115336.
Tatsumi N, Kumamoto Y. The role of IL-2 in type 2immunity[J]. Front Immunol, 2025, 16:1622187.
Hernandez R, Põder J, LaPorte K M, et al. Engineering IL-2 for immunotherapy of autoimmunity and cancer[J]. Nat Rev Immunol, 2022, 22(10):614-628.
Yang J B, Chen X, He X M, et al. Tanreqing injection demonstrates anti-dengue activity through the regulation of the NF-κB-ICAM-1/VCAM-1 axis[J]. Phytomedicine,2024, 130:155764.
Liu J, Jiang J X, Xu Q F, et al. Xuanfu Daizhe Tang alleviates reflux esophagitis in rats by inhibiting the STAT1/TREM-1 pathway[J]. J Ethnopharmacol, 2024,326:117903.
李玉玲.玉屏风散联合HAART对肺气虚证HIV/AIDS患者TNF-α、IL-1β、IL-2及IFN-γ水平的影响[D].长沙:湖南中医药大学, 2023.
Gocher A M, Workman C J, Vignali D A A. Interferon-γ:Teammate or opponent in the tumour microenvironment?[J]. Nat Rev Immunol, 2022, 22(3):158-172.
Ivashkiv L B. IFNγ:Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy[J]. Nat Rev Immunol, 2018, 18(9):545-558.
任振阳. CAFs通过IL-6抑制DC抗原交叉提呈介导肿瘤免疫逃逸及六味地黄丸的干预作用[D].广州:广州中医药大学, 2024.
冯鹏,胡珀,李慧,等.灵芝孢子粉在免疫调节中的作用及机制研究进展[J].药物生物技术, 2021, 28(3):308-314.
Manohar S M. At the crossroads of TNF-α signaling and cancer[J]. Curr Mol Pharmacol, 2024, 17:e060923220758.
Kureshi C T, Dougan S K. Cytokines in cancer[J]. Cancer Cell, 2025, 43(1):15-35.
Wu L J, Jin Y T, Zhao X, et al. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α[J]. Cell Metab, 2023, 35(9):1580-1596.
Zheng D, Guo W J, Zhao X L. Effects of Shenmai Injection(参麦注射液)combined with Meglumine Adenosine Cyclophosphate Injection on cardiac function and peripheral serum levels of TNF-α, TGF-β1 and IFN-γ in patients with viral myocarditis[J]. World J Integr Tradit West Med, 2020, 6(1):32-36.
郭胜男,曹昊,王丹,等.参麦注射液调控脂肪酸合成代谢改善肺腺癌顺铂耐药性的机制[J/OL].中国实验方剂学杂志,(2025-07-29)[2026-01-09]. https://doi.org/10.13422/j.cnki.syfjx.20251624.
Galassi C, Chan T A, Vitale I, et al. The hallmarks of cancer immune evasion[J]. Cancer Cell, 2024, 42(11):1825-1863.
Tufail M, Jiang C H, Li N. Immune evasion in cancer:Mechanisms and cutting-edge therapeutic approaches[J].Signal Transduct Target Ther, 2025, 10:227.
程权,傅华洲.中药复方防治胸部肿瘤治疗相关放射性肺损伤概况[J/OL].实用中医内科杂志,(2025-11-17)[2026-04-09]. https://link.cnki.net/urlid/21.1187.R.20251117.1040.004.
陈嘉怡,宋建,何家健,等.中药注射液辅助治疗非小细胞肺癌的研究进展[J].世界临床药物, 2024, 45(6):673-677.
秦磊,张晓春.参麦注射液对非小细胞肺癌生存期影响的回顾性研究[J].湖南中医杂志, 2025, 41(7):15-20.
闫靖楠,宋忠阳,祁亚锋,等.中药调控肿瘤免疫微环境的作用及机制研究进展[J].中草药, 2025, 56(17):6477-6492.
夏文婷,樊志敏,王璐.四君子汤及其活性成分调节肿瘤免疫微环境的研究进展[J].天津中医药, 2025,42(5):669-674.
汪莲芳,王佳华,柯刚,等.中药活性成分调控肿瘤微环境作用机制及纳米递送系统的研究进展[J].中草药, 2025, 56(7):2547-2558.
Liu R, Zeng L W, Li H F, et al. PD-1 signaling negatively regulates the common cytokine receptor γ chain via MARCH5-mediated ubiquitination and degradation to suppress anti-tumor immunity[J]. Cell Res, 2023, 33(12):923-939.
Lin X, Kang K, Chen P, et al. Regulatory mechanisms of PD-1/PD-L1 in cancers[J]. Mol Cancer, 2024, 23(1):108.
Ping Y, Shan J Q, Qin H M, et al. PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+T cell ferroptosis[J]. Immunity, 2024,57(9):2122-2139.
Gao Q, Sheng Q S, Yang Z J, et al. Honokiol-magnololbaicalin possesses synergistic anticancer potential and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer by triggering GSDME-dependent pyroptosis[J]. Adv Sci, 2025, 12(13):2417022.
Hao B J, Lin S M, Liu H P, et al. Baicalein tethers CD274/PD-L1 for autophagic degradation to boost antitumor immunity[J]. Autophagy, 2025, 21(5):917-933.
陈昱帆,李思聪,崔译元,等.扶正解毒化瘀法对免疫治疗减毒增效作用的研究进展[J].肿瘤防治研究,2025, 52(1):11-18.
Li J X, Li R Z, Sun A, et al. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing Decoction by suppression of PRKCA and sphingolipid signaling[J].Pharmacol Res, 2021, 171:105574.
Jiang X Y, Xu Z Y, Wang H, et al. Metabolomics and integrated network pharmacology analysis revealed multitargeted anti-cancer effect of Fuzhengxiaoji Decoction against non-small cell lung cancer[J]. Phytomedicine,2025, 143:156855.
He B, Cui J, Zhang Z W, et al. Combining network pharmacology and molecular docking to explore the pharmacological mechanism of Codonopsis Radix.-Hedysarum Multijugum Maxim.-Atractylodes Macrocephala Koidz. in treating lung cancer[J]. BMC Complement Med Ther, 2025, 25(1):66.
Fischer D S, Villanueva M A, Winter P S, et al. Adapting systems biology to address the complexity of human disease in the single-cell era[J]. Nat Rev Genet, 2025,26(8):514-531.
Castrillo J I, Oliver S G. Alzheimer’s as a systems-level disease involving the interplay of multiple cellular networks[J]. Methods Mol Biol, 2016, 1303:3-48.
Tang F C, Barbacioru C, Wang Y Z, et al. m RNA-Seq whole-transcriptome analysis of a single cell[J]. Nat Methods, 2009, 6(5):377-382.
Wu S Z, Al-Eryani G, Roden D L, et al. A single-cell and spatially resolved atlas of human breast cancers[J]. Nat Genet, 2021, 53(9):1334-1347.
Macosko E Z, Basu A, Satija R, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets[J]. Cell, 2015, 161(5):1202-1214.
Shi Z D, Liu Y, Tao Z Q, et al. Apigenin inhibits recurrent bladder cancer progression by targeting VEGF-β[J].Cancer Lett, 2025, 620:217676.
Zhang Y Y, Zhang Z M. The history and advances in cancer immunotherapy:Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J]. Cell Mol Immunol, 2020, 17(8):807-821.
Azizi E, Carr A J, Plitas G, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment[J]. Cell, 2018, 174(5):1293-1308.
Van de Sande B, Lee J S, Mutasa-Gottgens E, et al.Applications of single-cell RNA sequencing in drug discovery and development[J]. Nat Rev Drug Discov,2023, 22(6):496-520.
Wan L Y, Hao W T, Li L L, et al. Dissecting macrophage heterogeneity and kaempferol in lung adenocarcinoma:A single-cell transcriptomic approach and network pharmacology[J]. Discov Oncol, 2025, 16(1):104.
Zhou X Q, Gao J M, Zhang Y X, et al. Immunomodulatory effects of traditional Chinese medicine on cancer:Insights from network pharmacology and single-cell RNA sequencing data on the treatment of lung adenocarcinoma with Shenling Baizhu Powder[J]. Funct Integr Genomics,2025, 25(1):47.
Hashimoto K, Kouno T, Ikawa T, et al. Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians[J]. Proc Natl Acad Sci U S A, 2019,116(48):24242-24251.
Cao Y, Shen T, Huang X Q, et al. Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity[J]. Oncotarget, 2017, 8(3):4837-4848.
Lai H D, Cheng X M, Liu Q, et al. Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer[J]. Int J Cancer, 2021, 149(12):2099-2115.
杨继,张垚,杨培丽,等.类器官技术在中医药防治高血压领域研究中的应用价值[J].中草药, 2025, 56(21):7973-7982.
徐鑫梅,干志强,李睿琪,等.人工智能驱动的类器官/器官芯片:中药及民族药药效物质和靶标发现新范式[J].中草药, 2026, 57(1):1-12.
Kretzschmar K. Cancer research using organoid technology[J]. J Mol Med, 2021, 99(4):501-515.
Xu H X, Lyu X D, Yi M, et al. Organoid technology and applications in cancer research[J]. J Hematol Oncol, 2018,11(1):116.
Li H F, Zhang Y S, Lan X M, et al. Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/Akt and MAPK signaling pathways[J]. Front Cell Dev Biol, 2021, 9:773048.
Li Y F, Gao Y, Liang B W, et al. Patient-derived organoids of non-small cells lung cancer and their application for drug screening[J]. Neoplasma, 2020, 67(2):430-437.
Li T, Yang Y F, Yang F R, et al. Organoids and organoidson-chip in traditional Chinese medicine research:Applications, advantages, and future prospects[J]. Cell Biol Int, 2025, 49(10):1233-1244.
Yang J Y, Jiang Y, Li M X, et al. Organoid, organ-on-achip and traditional Chinese medicine[J]. Chin Med, 2025,20(1):22.
王忠,陈寅萤,张盈颖,等.多组分多靶点中药药理作用机制研究中的问题和解决策略[J].中国实验方剂学杂志, 2018, 24(5):1-6.
李蕙质,周小玲,杨玉杰,等.数据挖掘算法在中药方剂研究中的应用现状[J].中国药房, 2024, 35(1):112-118.
江启煜,孙晓生,谢波,等.中医智能推理辨证模型探索[J].世界科学技术-中医药现代化, 2024, 26(6):1644-1653.
付涛涛,陈艳梅,李庆娜,等.基于《中国药典》的中药知识图谱构建与应用[J].医学信息学杂志, 2024,45(10):33-39.
Xiao W K, Zhang M Q, Zhao D N, et al. TCMKD:From ancient wisdom to modern insights-a comprehensive platform for traditional Chinese medicine knowledge discovery[J]. J Pharm Anal, 2025, 15(6):101297.
Meng F B, Tang Q, Chu T Z, et al. TCMPG:An integrative database for traditional Chinese medicine plant genomes[J]. Hortic Res, 2022, 9:uhac060.
DeMeo B, Nesbitt C, Miller S A, et al. Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes[J]. Science, 2025,390(6776):eadi8577.
Ji Q, Zhu F S, Liu X, et al. Recent advance in applications of proteomics technologies on traditional Chinese medicine research[J]. Evid Based Complementary Altern Med, 2015, 2015(1):983139.
Cao H X, Zhang A H, Zhang H M, et al. The application of metabolomics in traditional Chinese medicine opens up a dialogue between Chinese and Western medicine[J].Phytother Res, 2015, 29(2):159-166.
Wu Z, Wang Z H, Chang X Y, et al. Prioritizing pathway signature using deep learning approach:A novel strategy for traditional Chinese medicine formula generation and optimization[J]. Brief Bioinform, 2025, 26(4):bbaf403.
Chi J H, Shu J M, Li M, et al. Artificial intelligence in metabolomics:A current review[J]. Trac Trends Anal Chem, 2024, 178:117852.
黄群富,丁长松.融入异构网络特征的深度学习预测中药靶点[J].智能计算机与应用, 2023, 13(1):158-163.
王艳菁,李治琦,魏冬青,等.基于人工智能SGRNTrans框架预测温胆汤中成分-靶点相互作用的研究[J].重庆医科大学学报, 2024, 49(8):1002-1011.
何威华,邓兰,蒋益兰.健脾消癌方对结肠癌肝转移裸鼠模型肿瘤微环境转移相关因子表达的影响[J].中国实验方剂学杂志, 2023, 29(3):81-87.

2026年第57卷第9期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.09.030

接收时间：2025-12-04
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-12-04

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.09.030

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT